Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMA

- PMLiVE

New EC anti-smoking plans include ban on flavoured tobacco

Pictorial health warnings on cigarettes and regulation for e-cigarettes also proposed

- PMLiVE

Celgene signs $500m antibody deal with Sutro

Joins list of companies with interest in antibody-drug conjugates

- PMLiVE

Fred Powell joins Celator as chief financial officer

Joins oncology specialist from OraPharma

- PMLiVE

Year-end FDA approvals for Novartis, GSK drugs

Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Roche’s Perjeta backed in EU for breast cancer

CHMP recommends use alongside Herceptin

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

- PMLiVE

Government wants Prof David Haslam to be new NICE chair

He would take over from Prof Sir Michael Rawlins in April

- PMLiVE

Boehringer takes leukaemia drug volasertib into phase III

Shows positive results in a difficult-to-treat patient population

- PMLiVE

ASH meeting hears of progress with myelofibrosis drugs

New studies suggest momentum is for use of Janus kinase (JAK) inhibitors

- PMLiVE

EMA: move to greater clinical trial transparency ‘irreversible’

New Europe data rules could be ready by 2014

- PMLiVE

Pfizer set for negative NICE decision on Inlyta

Institute's draft guidance doesn't recommend drug for advanced kidney cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links